Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Generic drug

Valproate price, strengths & recalls

Generic of Depakote

Pharmacies pay $5.87 for 30 tablets of Valproate 500 mg (24 hr) extended-release tablet this week, and from $1.60 to $7.27 across its 8 priced strengths and forms. 52 manufacturers make it. It is in shortage (unavailable). 1 recall is ongoing. Its official label last changed on December 12, 2025.

Unavailable1 open recallGeneric
Pharmacies pay$5.87for 30 tablets of 500 mg (24 hr) extended-release tablet+0.7% in 4 weeks
Fair cash price
$17.25
Strengths
8
Makers
52
Updated
Nov 11

Valproate price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
250 mg capsule$0.2422$7.27 / 30 capsules-0.2%-3.1%
125 mg delayed-release capsule$0.1971$5.91 / 30 capsules-1.8%-9.8%
125 mg delayed-release tablet$0.0532$1.60 / 30 tablets-3.2%-3.9%
250 mg delayed-release tablet$0.0847$2.54 / 30 tablets-1.1%-10.6%
500 mg delayed-release tablet$0.1561$4.68 / 30 tablets-2.9%-0.7%
250 mg (24 hr) extended-release tablet$0.1386$4.16 / 30 tablets+6.7%-0.2%
500 mg (24 hr) extended-release tablet$0.1957$5.87 / 30 tablets+0.7%+6.9%
100 mg/mL, 5 mL injectionNot priced this week
50 mg/mL oral solution$0.0335$6.71 / 200 mL+1.2%+3.3%

The lowest cost per tablet is 125 mg delayed-release tablet at $0.0532. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.

Brand names of valproate

A brand and its generic share the active ingredient; the generic is almost always far cheaper.

Supply status: shortages & recalls

In shortage2 products are short or being discontinued
1 ongoing recall10 recalls on record, latest Jul 29, 2026

Shortages

  • Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05)Fresenius Kabi USA, LLC · Unavailable · Reason: Demand increase for the drug · Updated Nov 3, 2026Next release November 2026. Check wholesalers for inventory.
  • Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10)Hikma Pharmaceuticals USA, Inc. · Available · Updated Oct 14, 2026Additional lots will be available. Product will be made available as it is released.

In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.

Recalls

Showing the 6 most relevant of 10 - all recalls.

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

What did you pay for valproate? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedDecember 12, 2025
Version18 of 18
EffectiveDec 11, 2025
Read the label

These highlights do not include all the information needed to use DIVALPROEX SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for DIVALPROEX SODIUM DELAYED-RELEASE TABLETS. DIVALPROEX SODIUM delayed-release tablets, for oral use Initial U.S. Approval: 1983

This drug has a boxed warning

WARNING: LIFE THREATENING ADVERSE REACTIONS

WARNING: LIFE THREATENING ADVERSE REACTIONS

See full prescribing information for complete boxed warning.

Hepatotoxicity, including fatalities, usually during the first 6 months of treatment. Children under the age of two years and patients with mitochondrial disorders are at higher risk. Monitor patients closely, and perform serum liver testing prior to therapy and at frequent intervals thereafter (

5.1)

Fetal Risk, particularly neural tube defects, other major malformations, and decreased IQ (

5.2,

5.3,

5.4)

Pancreatitis, including fatal hemorrhagic cases (

5.5)

Hepatotoxicity

General Population:Hepatic failure resulting in fatalities has occurred in patients receiving valproate and its derivatives. These incidents usually have occurred during the first six months of treatment. Serious or fatal hepatotoxicity may be preceded by non-specific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, and vomiting. In patients with epilepsy, a loss of seizure control may also occur. Patients should be monitored closely for appearance of these symptoms. Serum liver tests should be performed prior to therapy and at frequent intervals thereafter, especially during the first six months

[see

Warnings and Precautions (5.1)]

.

Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. When divalproex sodium delayed-release tablets are used in this patient group, it should be used with extreme caution and as a sole agent. The benefits of therapy should be weighed against the risks. The incidence of fatal hepatotoxicity decreases considerably in progressively older patient groups.

Patients with Mitochondrial Disease:There is an increased risk of valproate-induced acute liver failure and resultant deaths in patients with hereditary neurometabolic syndromes caused by DNA mutations of the mitochondrial DNA Polymerase

γ

(POLG) gene (e.g. Alpers-Huttenlocher Syndrome). Divalproex sodium delayed-release tablets are contraindicated in patients known to have mitochondrial disorders caused by POLG mutations and children under two years of age who are clinically suspected of having a mitochondrial disorder

[see

Contraindications (4)]

. In patients over two years of age who are clinically suspected of having a hereditary mitochondrial disease, divalproex sodium delayed-release tablets should only be used after other anticonvulsants have failed. This older group of patients should be closely monitored during treatment with divalproex sodium delayed-release tablets for the development of acute liver injury with regular clinical assessments and serum liver testing. POLG mutation screening should be performed in accordance with current clinical practice

[see

Warnings and Precautions (5.1)]

.

Fetal Risk

Valproate can cause major congenital malformations, particularly neural tube defects (e.g., spina bifida). In addition, valproate can cause decreased IQ scores and neurodevelopmental disorders following

in uteroexposure.

Valproate is therefore contraindicated for prophylaxis of migraine headaches in pregnant women and in women of childbearing potential who are not using effective contraception

[see

Contraindications (4)]

. Valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable.

Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. In such situations, effective contraception should be used

[see

Warnings and Precautions (5.2,

5.3,

5.4)]

.

A Medication Guide describing the risks of valproate is available for patients

[see

Patient Counseling Information (17)]

.

Pancreatitis

Cases of life-threatening pancreatitis have been reported in both children and adults receiving valproate. Some of the cases have been described as hemorrhagic with a rapid progression from initial symptoms to death. Cases have been reported shortly after initial use as well as after several years of use. Patients and guardians should be warned that abdominal pain, nausea, vomiting, and/or anorexia can be symptoms of pancreatitis that require prompt medical evaluation. If pancreatitis is diagnosed, valproate should ordinarily be discontinued. Alternative treatment for the underlying medical condition should be initiated as clinically indicated

[see

Warnings and Precautions (5.5)]

.

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
NDA018723 · Abbvie
First approved
March 10, 1983 (43 years ago)
Latest approved change
March 31, 2026
Approved label
PDF, Apr 2, 2026
Generic makers
29 approved generic applications on the market

Valproate questions

How much does valproate cost without insurance?

Pharmacies pay about $5.87 for 30 tablets of valproate 500 mg (24 hr) extended-release tablet ($0.1957 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $17.25. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

What is the brand name of valproate?

Valproate is sold as Depakote. The generic has the same active ingredient and usually costs far less.

Is valproate in shortage?

Yes. 2 products are listed as in shortage or being discontinued (unavailable). See which ones.

Has valproate been recalled?

10 recalls on record, 1 ongoing. Recalls name specific lots - check yours.

When did the valproate label last change?

The official label was last updated on December 12, 2025 (version 18). See what changed.

Talk about valproate

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.